Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Forma Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have documented IDH1-R132 gene-mutated disease as evaluated by site
Glioma: Advanced glioma that has recurred or progressed following standard therapy, or that has not responded to standard therapy.
Hepatobiliary cancer that is relapsed/refractory or intolerant to approved standard-of-care therapy (including: hepatocellular carcinoma, bile duct carcinoma, intrahepatic cholangiocarcinoma or other hepatobiliary carcinomas)
Chondrosarcoma that is relapsed or refractory and either locally advanced or metastatic and not amenable to complete surgical excision
You may not be if
Other solid tumors that have relapsed or refractory to standard-of-care therapy with no other available therapeutic options
Good performance status
Good kidney and liver function
Prior solid organ or hematopoietic cell transplant
Prior treatment with IDH1 inhibitor (single agent cohorts only)
Congestive heart failure (New York Heart Association Class III or IV) or unstable angina pectoris. Previous history of myocardial infarction within 1 year prior to study entry, uncontrolled hypertension or uncontrolled arrhythmias
Unstable or severe, uncontrolled medical condition (e.g., unstable cardiac function, unstable pulmonary condition, including pneumonitis and/or interstitial lung disease, and uncontrolled diabetes)
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
PD-1 only: active autoimmune disease
Clareo Health | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
